{"url_path":"/sec/ostx/8-k/2026-07-02/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1795091/0001213900-26-075013-index.html","accession_number":"0001213900-26-075013","cik":"0001795091","ticker":"OSTX","issuer_name":"OS Therapies Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1795091/0001213900-26-075013-index.html","primary_entity_key":"0001795091","primary_entity_name":"OS Therapies Inc"},"word_count":338,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 1, 2026, Karim Galzahr\nnotified the Company of his resignation from the Company’s board of directors, effective immediately. Mr. Galzahr’s resignation\nwas not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.\n\n \n\nOn June 1, 2026, the Company’s\nboard of directors appointed Dr. Craig Eagle to the board of directors to fill the vacancy created by Mr. Galzahr’s resignation,\neffective immediately. Dr. Eagle currently serves in an advisory capacity to the Company as its Chief Medical Advisor.\n\n \n\nDr. Eagle has served as Chief\nMedical Officer of Guardant Health, Inc. (Nasdaq: GH) since May 2021. From 2019 to May 2021, he served as Vice President, Medical Affairs\nOncology at Genentech, where he was responsible for medical programs across the oncology portfolio and supported the development of clinical\ntrial strategies in personalized medicine. Prior to Genentech, Dr. Eagle spent approximately 10 years at Pfizer Inc. in a series of senior\nleadership roles, including Oncology Business Lead for the United Kingdom and Canada, Global Lead for Oncology Strategic Alliances and\nPartnerships, and Global Head of the Oncology Therapeutic Area Global Medical and Outcomes Group, where he also oversaw the U.S. oncology\nbusiness. Dr. Eagle received his medical degree from the University of New South Wales in Sydney, Australia and completed his internal\nmedicine training at Royal North Shore Hospital in Sydney.\n\n \n\nThere are no family relationships\nbetween Dr. Eagle and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d)\nof Regulation S-K. In addition, there are no transactions between Dr. Eagle and the Company that would be required to be disclosed pursuant\nto Item 404(a) of Regulation S-K.\n\n \n\nDr. Eagle has not entered\ninto any compensatory arrangement with the Company in connection with his appointment to the Board other than the standard compensation\narrangements applicable to non-employee directors.\n\n \n\n5"}